Predictive Oncology (NASDAQ: POAI), a knowledge-driven
company focused on applying artificial intelligence (“AI”) to personalized
medicine and drug discovery, on Wednesday announced that it has entered into an
exchange agreement with POAI chief executive officer Dr. Carl Schwartz
regarding a $2.1 million promissory note of the company. Per the agreement, Dr.
Schwartz has exchanged the note for 1,533,481 shares of newly issued common
stock at an exchange rate of $1.43 each, the closing price of the common stock
on April 21, 2020. Dr. Schwartz agreed to not sell or transfer 766,740 shares
(one-half of the shares) for three months after the date of the exchange
agreement, and to not sell or transfer the remaining 766,741 shares for a
period of six months following the agreement. Additional details concerning the
agreement are available at www.SEC.gov on
the company’s Form 8-K filed on April 22, 2020. “This agreement enables the
company to strengthen its balance sheet and simplify its capital structure at a
critical juncture in our quest to commercialize our highly valuable database of
cancer tumors for the advancement of predictive medicine. At the same time, it
reinforces my commitment and demonstrates my beliefs in our ability to emerge
as a leader in the application of artificial intelligence to oncology
therapies,” Predictive Oncology CEO Dr. Carl Schwartz stated in the news
release.
To view the full press release, visit http://ibn.fm/mT1Yd
About Predictive Oncology Inc.
Predictive Oncology operates through three segments
(domestic, international and other) that contain four subsidiaries; Helomics,
TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial
intelligence to its rich data gathered from patient tumors to both personalize
cancer therapies for patients and drive the development of new targeted
therapies in collaborations with pharmaceutical companies. Helomics’
CLIA-certified lab provides clinical testing that assists oncologists in
individualizing patient treatment decisions, by providing an evidence-based
road map for therapy. In addition to its proprietary precision oncology
platform, Helomics offers boutique CRO services that leverage its TruTumor(TM),
patient-derived tumor models coupled to a wide range of multi-omics assays
(genomics, proteomics and biochemical), and an AI-powered proprietary
bioinformatics platform to provide a tailored solution to its clients’ specific
needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid
approach to growing tumors in the laboratory, which essentially “fools” cancer
cells into thinking they are still growing inside a patient. Its proprietary
Oncology Discovery Technology Platform Kits will assist researchers and
clinicians to identify which cancer cells bind to specific biomarkers. Once the
biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture
Technology Platforms, which isolate and help categorize an individual patient’s
heterogeneous tumor samples to enable the development of patient-specific
treatment options. Helomics and TumorGenesis are focused on ovarian cancer.
Predictive Oncology’s Skyline Medical division markets its patented and
FDA-cleared STREAMWAY System, which automates the collection, measurement and
disposal of waste fluid, including blood, irrigation fluid and others, within a
medical facility, through both domestic and international divisions. The
company has achieved sales in five of the seven continents through both direct
sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
